The mission of the Case CCC Tissue Resources Core Facility is to coordinate five services: tissue procurement, biorepository, tissue processing, histology, and immunohistochemistry (IHC). Tissue procurement prospectively collects, prepares, and distributes human tissue samples and associated deidentified data directly to investigators and/or to the biorepository, tissue processing, histology, and IHC components. Within these components, services such as tissue microarrays (TMAs), immunofluorescence, in situ hybridization, microscopy and digital imaging, and laser capture microdissection (LCM) are provided for both procured human tissue and animal research tissues transferred to the Core by investigators. The Core collaborates with researchers to assist them as needed in the IRB approval process, to advise them on sample availability, and to perform special tissue collection, dissection, and processing procedures. Malignant, pre-malignant benign, diseased, and normal tissues are obtained from surgical resections and autopsies. Normal adjacent tissue and tissues from different organ sites from the same donor are also available to researchers. All work is conducted in a manner that preserves sample integrity, protects donor identity, and facilitates the minimization of disruptions to surgical operating rooms and surgical pathology units during the collection process. The Tissue Resources Core is a critical resource for projects requiring human tissues for research and services that are not easily duplicated in other laboratories, such as automated IHC;or are significantly limited when accessed through a resource such as clinical pathology laboratories of area hospitals. Members from all the research programs use the services on a large scale. Access to clinical archived FFPE tissues has high impact on research projects, since large numbers of samples with clinical annotations and outcome data may be obtained within a short period of time. In continuation of its record of contributions to the advancement of science in past years, the Tissue Resources Core facilitates the research Case CCC members conduct. Services and materials provided by the Core have assisted research in gastrointestinal, breast, female genital, hematopoietic, lung, brain and prostate cancer. During the period 2006-2012 there were >74 publications from Case CCC members in journals such as J Pathol, Prostate, Oncogene, Clin Cancer Research, Neoplasia, Int J Cancer, Cancer Epidemiol Biomarkers, and Lung Cancer.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Anderson, Christian E; Wang, Charlie Y; Gu, Yuning et al. (2018) Regularly incremented phase encoding - MR fingerprinting (RIPE-MRF) for enhanced motion artifact suppression in preclinical cartesian MR fingerprinting. Magn Reson Med 79:2176-2182
Burger, Denis R; Parker, Yvonne; Guinta, Kathryn et al. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant 24:260-266
Shi, Xiaojun; Wang, Bingcheng (2018) Caught in the ""Akt"": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF. Sci Signal 11:
Tartakoff, Alan Michael; Dulce, David; Landis, Elizabeth (2018) Delayed Encounter of Parental Genomes Can Lead to Aneuploidy in Saccharomyces cerevisiae. Genetics 208:139-151
Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643

Showing the most recent 10 out of 1227 publications